Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.
1. A method to improve the efficacy and/or reduce the side effects of suboptimally administered drug therapy comprising the steps of:
(a) identifying at least one factor or parameter associated with the efficacy and/or occurrence of side effects of the drug therapy, wherein the factor or parameter is additionally associated with at least one of: (i) the specific disease or condition being treated; (ii) the stage of the disease or condition being treated; (iii) selection of an appropriate patient for treatment; (iv) selection of an appropriate phenotype of the patient or the disease or condition being treated; and (v) selection of an appropriate phenotype of the patient or the disease or condition being treated; and
(b) modifying the factor or parameter to improve the efficacy and/or reduce the side effects of the drug therapy;
wherein the drug therapy comprises administration of bisantrene and wherein the disease or condition being treated is a cancer selected from the group consisting of refractory breast cancer, breast cancer characterized by overexpressed Her-2-neu, triple-negative breast cancer, acute myelocytic leukemia, and acute leukemias of childhood.
2. The method of claim 1 wherein the improvement is made by an indication for use.
3. The method of claim 2 wherein the indication for use is selected from the group consisting of:
(a) use for treatment of refractory breast cancer;
(b) use for treatment of triple-negative breast cancer;
(c) use for treatment of acute myelocytic leukemia (AML);
(d) use for treatment of acute myelocytic leukemia (AML) and acute lymphocytic leukemia (ALL) of childhood; and
(e) use for treatment of breast cancer characterized by overexpressed Her-2-neu.
4. The method of claim 1 wherein the improvement is made by selection of disease stage.
5. The method of claim 4 wherein the disease stage is selected from the group consisting of:
(a) use to induce angiogenesis inhibition to prevent or limit metastatic spread;
(b) use for recurrent leukemia; and
(c) use for recurrent breast cancer.
6. The method of claim 1 wherein the improvement is made by patient selection.
7. The method of claim 6 wherein the patient selection is a patient selection carried out by a criterion selected from the group consisting of:
(a) selecting patients with a disease condition characterized by a high level of a metabolic enzyme selected from the group consisting of histone deacetylase, protein kinases, and ornithine decarboxylase;
(b) selecting patients with a disease condition characterized by a low level of a metabolic enzyme selected from the group consisting of histone deacetylase, protein kinases, and ornithine decarboxylase;
(c) selecting patients with a low or high susceptibility to a condition selected from the group consisting of thrombocytopenia and neutropenia;
(d) selecting patients intolerant of GI toxicities;
(e) selecting patients characterized by over- or under-expression of a gene selected from the group consisting of jun, GPCRs, signal transduction proteins, VEGF, prostate specific genes, protein kinases, and telomerase;
selecting patients as the result of immune screening;
(g) selecting patients as the result of DNA methylation screening;
(h) selecting patients with recurrent disease characterized by the duration of their initial response;
(i) selecting patients without mutations in p53; and
(j) selecting for patients without extensive prior treatment.